{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Bezlotoxumab: A New Drug for the Toxic Effects of Clostridium Difficile

Purpose of Activity

To provide information about the new drug bezlotoxumab.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Describe Clostridium difficile (C. diff) infection and the challenges of its treatment.
  2. Explain the mechanism of action, dosage and administration, contraindications, and side effects of bezlotoxumab.
Price: $10.00


  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223. Your certificate is valid in all states.

Test Code: GN0717B
Published: Jul/Aug 2017
Expires: 6/8/2019
Passing Score: 9/12 (75%)
Authors: Mark D. Welliver, DNP, CRNA, ARNP
Specialties: Gastroenterology